在放射标记的纳米颗粒进度中探索创新的进步，用于多模态癌症成像和静脉
Exploring innovative strides in radiolabeled nanoparticle progress for multimodality cancer imaging and theranostic applications
影响因子:3.50000
分区:医学2区 / 肿瘤学2区 核医学2区
发表日期:2024 Sep 20
作者:
Atena Najdian, Davood Beiki, Milad Abbasi, Ali Gholamrezanezhad, Hojjat Ahmadzadehfar, Ali Mohammad Amani, Mehdi Shafiee Ardestani, Majid Assadi
摘要
多模式成像作为一种创新方法展开，该方法在同时或顺序地采用了一系列成像技术。计算机断层扫描（CT），磁共振成像（MRI），单光子发射计算机断层扫描（SPECT），正电子发射断层扫描（PET）和光学成像（OI）的整合导致对复杂生物学过程的全面和互补的理解。这种创新的方法结合了每种方法的优势并克服了他们的个人局限性。通过和谐地融合了这些模式的数据，它可以显着提高癌症诊断的准确性，并有助于治疗决策过程。纳米颗粒具有带有放射性同位素和多种对比剂的可容纳功能化的高潜力。这种战略修改可增强信号放大，显着提高图像敏感性并提高对比度指标。这种量身定制的纳米颗粒构造表现出在临床前和临床环境中推进成像方式的有前途的途径。此外，纳米颗粒是成像剂和治疗有效载荷共定位的统一纳米平台，从而优化了癌症管理策略的效率。因此，放射性标记的纳米颗粒在推动多模式成像和静脉应用领域的领域表现出巨大的潜力。这篇综述讨论了分子成像在癌症诊断中的潜在应用，基于纳米技术的放射性标记材料在多模式成像和疗法应用中的利用以及该领域的最新进展。它还突出了包括细胞毒性和调节性依从性在内的挑战，这是对多模式成像和疗法应用中纳米核药物的有效临床翻译的必要考虑因素。
Abstract
Multimodal imaging unfolds as an innovative approach that synergistically employs a spectrum of imaging techniques either simultaneously or sequentially. The integration of computed tomography (CT), magnetic resonance imaging (MRI), single-photon emission computed tomography (SPECT), positron emission tomography (PET), and optical imaging (OI) results in a comprehensive and complementary understanding of complex biological processes. This innovative approach combines the strengths of each method and overcoming their individual limitations. By harmoniously blending data from these modalities, it significantly improves the accuracy of cancer diagnosis and aids in treatment decision-making processes. Nanoparticles possess a high potential for facile functionalization with radioactive isotopes and a wide array of contrast agents. This strategic modification serves to augment signal amplification, significantly enhance image sensitivity, and elevate contrast indices. Such tailored nanoparticles constructs exhibit a promising avenue for advancing imaging modalities in both preclinical and clinical setting. Furthermore, nanoparticles function as a unified nanoplatform for the co-localization of imaging agents and therapeutic payloads, thereby optimizing the efficiency of cancer management strategies. Consequently, radiolabeled nanoparticles exhibit substantial potential in driving forward the realms of multimodal imaging and theranostic applications. This review discusses the potential applications of molecular imaging in cancer diagnosis, the utilization of nanotechnology-based radiolabeled materials in multimodal imaging and theranostic applications, as well as recent advancements in this field. It also highlights challenges including cytotoxicity and regulatory compliance, essential considerations for effective clinical translation of nanoradiopharmaceuticals in multimodal imaging and theranostic applications.